



The Scandinavian Society of Neuro-Oncology Meeting 2016 in Copenhagen

Program

(May be subject to changes)

Thursday, May 19

- | | |
|--------------------|--|
| 10.00-12.00 | Registration |
| 12.00-12.45 | Lunch |
| 12.45-12.55 | Opening Words
<i>Hans Skovgaard Poulsen, President of SNOG</i> |
| 12.55-13.40 | Advanced molecular diagnostics and the new WHO classification of gliomas
Speaker: <i>Guido Reifenberger</i> |
| 13.40-14.40 | Session 1: Basal Biology
<i>Chairs: Bjarne Winther Kristensen and Ulrik Lassen</i> |
| 13.40-13.50 | S 1.1 Non-metabolic function of phosphofructokinase-1 in glioblastoma maintenance. <i>Kamilla E. Jensen, Elisabeth A. Obara, Madhvasai K. Gajjar, Jiri Bartek Jr., Jane Skjøth-Rasmussen, Jannick Brennum, Jeremy N. Rich, <u>Petra Hamerlik</u></i> |
| 13.50-14.00 | S 1.2 VEGF-C contributes to autocrine VEGF Receptor 2 signaling and cellular maintenance in Glioblastoma. <i><u>Signe R. Michaelsen</u>, Mette K. Nedergaard, Helle Broholm, Jirina Bartkova, Mikkel Staberg, Thomas Urup, Manish Aghi, Slávka Lucacova, Mette Vilingshøj, Pia Pedersen, Andreas Kjær, Lara Perryman, Janine T. Erler, Jiri Bartek, Ulrik Lassen, Marie-Thérèse Stockhausen, Hans S. Poulsen and Petra Hamerlik</i> |
| 14.00-14.10 | S 1.3 Laminin modifications attract glioblastoma cells to invade the perivascular niche. <i><u>Lara Perryman</u>, Anette M Høye, Thomas R Cox, Jan Strøbech, Lidia Leonte, Lukram B Singh, Sergey Popov, Hans Skovgaard Poulsen, Chris Jones, Janine T Erler</i> |
| 14.10-14.20 | S 1.4 Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting. <i><u>Sune Munthe</u>, Mia Dahl Sørensen, Mads Thomassen, Mark Burton, Torben A. Kruse, Justin D. Lathia, Frantz Rom Poulsen, Bjarne Winther Kristensen</i> |

- 14.20-14.30 **S 1.5** Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis. Tor-Christian Aase Johannessen, Joydeep Mukherjee, Pavithra Viswanath, Shigeo Ohba, Sabrina M. Ronen, Rolf Bjerkvig and Russell O. Pieper
- 14.30-14.40 **S 1.6** The role of Lrig1 and Lrig3 in PDGF-induced experimental glioma. Camilla Holmlund, Mao Feng, Thais Langer Jacobus, Wanzhong Wang, Roger Henriksson, Håkan Hedman
- 14.40-15.10 **Coffee Break**
- 15.10-16.10** **Session 2: Biomarkers**
Chairs: Bjarne Winther Kristensen and Ulrik Lassen
- 15.10-15.20 **S 2.1** Quantitative and allelic methylation analyses of MGMT in glioblastoma. Lasse Sommer Kristensen, Signe Regner Michaelsen, Henrik Dyrbye, Derya Aslan, Kirsten Grunnet, Ib Jarle Christensen, Hans Skovgaard Poulsen, Kirsten Grønbæk, and Helle Broholm
- 15.20-15.30 **S 2.2** MGMT status in patients with glioblastoma multiforme. Rikke H. Dahlrot, Stine A. Petterson, Karin de Stricker, Jacob Hjelmberg, Steinbjørn Hansen, Bjarne Winther Kristensen
- 15.30-15.40 **S 2.3** ELMO 3 expression in metastasizing malignant gliomas. Helle Broholm, Linea Melchior, Morten Grauslund, Michael Kosteljanetz, Lasse Sommer Kristensen
- 15.40-15.50 **S 2.4** KIAA1549-BRAF Fusion-independent RSK Expression in Pilocytic Astrocytoma. Ausrine Areskeviciute, Cathrine Sandager Budtz, Karsten Nysom, Morten Grauslund, Helle Broholm
- 15.50-16.00 **S 2.5** Coregistration of histopathology with MRI reveals tumor invasion by low-grade gliomas. Kenney Roodakker
- 16.00-16.10 **S 2.6** Tumor-associated microglia/macrophages hold a poor prognostic value in high-grade gliomas and are associated with the mesenchymal subtype. Mia D Sørensen, Rikke H Dahlrot, Steinbjørn Hansen, Bjarne W Kristensen
- 16.10-16.40 **Break and Refreshments**
- 16.40-17.00 **Talk**
Patient
- 17.00-18.00 **Special Lecture:**
Søs Egelind

Friday 20 May 2016

- 9.00-9.45 Proton therapy
Speakers: Petra Witt Nyström and Morten Høyer
- 9.45-10.15 Session 3: Imaging**
Chairs: Ian Law and Roger Henriksson
- 9.45-9.55 **S 3.1** Pilot analysis of early treatment response by parametric response maps in malignant glioma. Preliminary results from an ongoing MRI study.
Anna Rydelius, Björn Lampinen, Jimmy Lätt, Johan Bengzon, Sara Kinhult, Pia C Sundgren, Silke Engelholm
- 9.55-10.05 **S 3.2** Comparison of ultrasound- and MRI-based tumour delineation in patients with low-grade gliomas (LGG). *Bodil Munkvold, Hans Kristian Bø, Erik Magnus Berntsen, Asgeir Jakola, Ingerid Reinertsen, Geirmund Unsgård, Ole Solheim*
- 10.05-10.15 **S 3.3** Patterns of failure for patients with glioblastoma following O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET- and MRI-guided radiation therapy.
Michael Lundemann, Junia Cardoso Costa, Ian Law, Svend Aage Engelholm, Aida Muhic, Hans Skovgaard Poulsen, Per Munck af Rosenschold
- 10.15-10.45 **Coffee break**
- 10.45-11.35 Session 4: Prognostic studies**
Chairs: Ian Law and Roger Henriksson
- 10.45-10.55 **S 4.1** FGFR3 staining as a marker for FGFR3 fusions and poor prognosis in diffuse gliomas. *Kirsi J. Granberg, Matti Annala, Birgitta Lehtinen, Juha Kesseli, Joonas Haapasalo, Olli Yli-Harja, Tapio Visakorpi, Hannu Haapasalo, Matti Nykter, Wei Zhang*
- 10.55-11.05 **S 4.2** Cripto-1: A Post-Operative Prognostic Biomarker for Glioblastoma Multiforme. *Neel Ingemann Nissen, Eva Hede Olsen, Pia Olesen, Linda Pilgaard and Meg Duroux*
- 11.05-11.15 **S 4.3** Prognostic and Predictive Biomarkers in Recurrent WHO Grade 3 Malignant Glioma Patients Treated with Bevacizumab and Irinotecan. *Toft A, Urup T, Grunnet K, Christensen IJ, Michaelsen SR, Broholm H, Lukram B, Larsen VA, Kosteljanetz M, Lassen U, Poulsen HS*
- 11.15-11.25 **S 4.4** The Prognostic Value of FET PET at Radiotherapy Planning in Newly Diagnosed Glioblastoma. *Sidsel Højklint Poulsen, Thomas Urup, Kirsten Grunnet, Vibeke Andrée Larsen, Per Munck af Rosenschöld, Hans Skovgaard Poulsen, Ian Law*
- 11.25-11.35 **S 4.5** The prognostic role of the proliferation marker Ki-67 in gliomas taking tumor heterogeneity and MGMT status into account. *Julie Amanda Bangsø, Rikke H. Dahlrot, Ann Mari Rosager, Steinbjørn Hansen, Bjarne W. Kristensen*

11.35-12.20 Immunotherapy of glioblastoma: a new horizon.
Speaker: Michael Weller

12.20-13.20 **Lunch**

13.20-14.05 The Role of Molecular Imaging in Brain Tumours
Speaker: Christian la Fougère

14.05-16.05 **Session 5: Experimental treatment**
Chairs: Petra Hamerlik and Rolf Bjerkvig

14.05-14.15 **S 5.1** The Human Glioma Cell Culture initiative: an open resource of primary cultures of glioma, applicable to prospective pharmacogenomic modeling of brain cancer. *Linnéa Schmidt, Patrik Johansson, Sathishkumar Baskaran, Yuan Xie, Tobias Bergström, Anna Segerman, Gregorz Wicher, Mia Niklasson, Damian Matuzewski, Ludmila Elfineh, Maria Häggblad, Ulf Mertens, Marianne Kastemar, Annika Hermansson, Ida Sintorn, Bo Lundgren, Rebecka Jörnsten, Bengt Westermark, Ingrid Lönnstedt, Lene Uhrbom, Cecilia Krona, Karin Forsberg-Nilsson, Sven Nelander*

14.15-14.25 **S 5.2** Peptide-based targeting of malignant gliomas. *Maija Hyvönen, Pauliina Turunen, Harri Sihto, Pauliina Filppu, Hannakaisa Jaatinen, Heikki Joensuu, Olli Tynnenen, Juha E. Jääskeläinen, Kaisa Lehti and Pirjo Laakkonen*

14.25-14.35 **S 5.3** Effect of suicide gene therapy on normal brain cells: how does the brain respond to HSV-Tk mediated therapy in a rat model. *Jubayer Al Hossain, Lars Romø Ystaas, Jelena Mrdalj, Kristjan Vaelk, Kristoffer Riecken, Boris Fehse, Rolf Bjerkvig, Janne Grønli and Hrvoje Miletic*

14.35-14.45 **S 5.4** Inhibition of class I histone deacetylases sensitizes glioblastoma cells to lomustine treatment. *Mikkel Staberger, Signe Regner Michaelsen, Rikke Darling Rasmussen, Mette Villingshøj, Petra Hamerlik, and Hans Skovgaard Poulsen*

14.45-14.55 **S 5.5** Drug repurposing shows that β -sitosterol effectively inhibits melanoma brain metastasis in experimental animal models. *Terje Sundstrøm, Jobin K. Varughese, Lars Prestegarden, Francisco Azuaje, Gro Vatne Røsland, Kai Ove Skafnesmo, Elizabeth S. Ingham, Lisa Even, Sarah Tam, Clifford G. Tepper, Kjell Petersen, Katherine W. Ferrara, Karl Johan Tronstad, Morten Lund-Johansen, Rolf Bjerkvig, Frits Thorsen*

14.55-15.05 **S 5.6** EGFR is upregulated in invasive recurrent tumors after suicide-mediated gene therapy of glioblastoma xenografts. *Ystaas LR, Hussain J., Talasila KM, Bjerkvig R., Miletic H*

15.05-15.35 **Coffee break**

Presentation of abstracts (Session 5 continued)

- 15.35-15.45 **S 5.7** Thioridazine sensitizes glioblastoma cells to temozolomide by impairing autophagy. Lars Prestegarden, Tor-Christian Aase Johannessen, Mahdi Hasan, Huaiyang Zhu, Oxana Denisova, Terje Sundstrøm, Jian Wang, Morten Lund-Johansen, Bassam Janji, Jukka Westermarck and Rolf Bjerkgvig
- 15.45-15.55 **S 5.8** Update of valganciclovir add-on therapy in glioblastoma. Effect in newly diagnosed and in recurrent patients. G Stragliotto, A Rahbar, C Söderberg-Naucler
- 15.55-16.05 **S 5.9** Cannabidiol improves the efficacy of bevacizumab treatment in glioblastoma by targeting HIF-1a. Obad N, Janji B, Espedal H, Keunen O, Hasan-Olive MM, Prestegarden L, Sakariassen P Ø, Niclou SP, Lund-Johansen M, Bjerkgvig R
- 16.05-16.25** **Session 6: Quality of Life**
Chairman: Hans Skovgaard Poulsen
- 16.05-16.15 **S 6.1** Specific needs and preferences among patients with high-grade gliomas and their caregivers. Piil K, Jarden M, Jakobsen J, Christensen K, Juhler M
- 16.15-16.25 **S 6.2** Risk for prescription of psychotropic drugs among partners of glioma patients: A nationwide registry study. Maria R. N. Jansson, Annika B. von Heymann-Horan, Birthe K. Rasmussen, Vanna Albieri, Birthe K. Rasmussen, Christoffer Johansen, Pernille E. Bidstrup
- 16.25-16.45 **Break and Refreshments**
- 16.45-17.00 Discussion on Novocure
Roger Henriksson
- 17.00-18.00 Music Therapy
Special Lecture: Peter Vuust
- 19.00-23.00 Conference dinner at Hotel Admiral

Saturday 21 May 2016

- 9.00-9.40 Convection-enhanced delivery for Brain Tumors
Speaker: John Sampson
- 9.40-10.10** **Session 7: Surgery**
Chairs: Michael Kosteljanetz and Hans Skovgaard Poulsen
- 9.40-9.50 **S 7.1** Initial surgical management of low-grade gliomas: an updated survival analysis from a norwegian comparative effectiveness study. Asgeir Jakola
- 9.50-10.00 **S 7.2** The surgeon may be aided in the delicate onco-funtional balance in resection of malignant gliomas by the combined use of 5-ALA and awake

craniotomy with cortical and subcortical mapping. Jane Skjøth-Rasmussen, Christina Malling-Engelmann, Jannick Brennum

- 10.00-10.10 **S 7.3** Feasibility of Early Postoperative ¹⁸F-FET PET/MRI after Surgery for Pediatric Patients with Brain Tumors. Lisbeth Marner, Karsten Nysom, Astrid Sehested, Lise Borgwardt, René Mathiasen, Peder Skov Wehner, Otto M Henriksen, Per Munck af Rosenschöld, Carsten Thomsen, Lars Bøgeskov, Helle Broholm, David Scheie, Marianne Juhler, Liselotte Højgaard, Ian Law
- 10.10-10.40 **Coffee break**
- 10.40-11.40** **Session 8: Clinical treatment**
Chairs: Hanna Mäenpää and Roger Henriksson
- 10.40-10.50 **S 8.1** Efficacy of vincristine, carmustine and bevacizumab on relapsed adult supratentorial anaplastic ependymoma, a case report. Dorota Goplen
- 10.50-11.00 **S 8.2** How has treatment of glioblastoma according to the Stuppregimen changed survival rates in Jonkoping County, Sweden? Helena Bruhn
- 11.00-11.10 **S 8.3** Neoadjuvant temozolomide treatment for anaplastic astrocytoma and glioblastoma: a randomized study. A Malmström, H Skovgaard Poulsen, B-H Grønberg, S Hansen, G Stragliotto, T Asklund, M Lysiak, J Dowsett, O Casar-Borota, B Winther Kristensen, P Söderkvist, J Rosel, R Henriksson
- 11.10-11.20 **S 8.4** Effects of bevacizumab combination therapy on transcriptional changes in responding and non-responding recurrent glioblastoma patients. Thomas Urup, Signe Regner Michaelsen, Line Mærsk Staunstrup, Kristoffer Vitting-Seerup, Marc Bennedbæk, Anders Toft, Lars Jønson, Helle Broholm, Petra Hamerlik, Hans Skovgaard Poulsen and Ulrik Lassen
- 11.20-11.30 **S 8.5** Impact of Renin-angiotensin System Blockade on Clinical Outcome in Glioblastoma Patients. Maria Dinche Johansen, Thomas Urup, Camilla Bjørnbak Holst, Søren Friis and Hans Skovgaard Poulsen
- 11.30-11.50 Neuro-Oncology – A historical perspective with special reference to Denmark
Michael Kosteljanetz
- 11.50-12.00 Closing words
- 12.00** **Lunch (lunch bag to-go)**